The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer. The Phase
The approval was based on data from Archer 1050 randomized, multicenter, multinational and open-label phase 3 study conducted in patients with unresectable, metastatic or recurrent NSCLC harboring EGFR
Pegfilgrastim is a long-acting version of filgrastim and may be prescribed to appropriate cancer patients undergoing chemotherapy to enhance the production of infection-fighting white blood cells2. Studies have
As part of a research and license agreement, Astellas Pharma will be able to use Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. The
Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based
The designation has been provided based on Phase II data from the Sprint trial, which evaluated selumetinib as an oral monotherapy in pediatric patients aged three years or
AJOVY is a humanized monoclonal antibody (mAb) that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. AJOVY is the first and
TUDORZA PRESSAIR is indicated for the maintenance treatment of patients with COPD. According to Kenneth Chapman, MD, Clinical Researcher, Krembil Research Institute, University Health Network, University of Toronto,
Boehringer Ingelheim, along with nanoPET Pharma, will use the MacroDel biologics-delivery platform to develop novel therapeutics. nanoPET Pharma is a former shareholder of ICD Therapeutics. nanoPET Pharma managing
As part of the global development and commercialization collaboration, AstraZeneca and Daiichi Sankyo will develop and commercialize trastuzumab deruxtecan (DS-8201), which is an antibody-drug conjugate (ADC) and potential
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.